The estimated Net Worth of Russell Greig is at least $21.2 mil dollars as of 28 July 2021. Russell Greig owns over 3,750 units of BiomX Inc stock worth over $3,713 and over the last 5 years he sold PHGE stock worth over $0. In addition, he makes $17,534 as Independent Chairman of the Board at BiomX Inc.
Russell has made over 1 trades of the BiomX Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 3,750 units of PHGE stock worth $15,000 on 28 July 2021.
The largest trade he's ever made was buying 3,750 units of BiomX Inc stock on 28 July 2021 worth over $15,000. On average, Russell trades about 625 units every 0 days since 2020. As of 28 July 2021 he still owns at least 3,750 units of BiomX Inc stock.
You can see the complete history of Russell Greig stock trades at the bottom of the page.
Dr. Russell George Greig Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Greig has served as a director and chairman of the Board of the Company since October 2019. Dr. Greig has more than 35 years’ experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline (“GSK”), where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, Dr. Greig was also President of SR One, GSK’s corporate venture group. He is currently Chairman of Mint Solutions (The Netherlands), Merus N.V. (NYSE: MRUS), eTheRNA immunotherapies NV (Belgium), and Sanifit (Spain). In addition, Dr. Greig previously served on the boards of Tigenix N.V. (acquired by Takeda Pharmaceutical Company Limited), and Ablynx N.V. (acquired by Sanofi, France). He was previously Chairman of Syntaxin Ltd (UK) (sold to Ipsen), Novagali Pharma S.A. (France) (acquired by Santen Pharmaceutical Co., Ltd.), and Isconova AB (Sweden) (acquired by Novavax, Inc. (Nasdaq: NVAX)). He served as acting Chief Executive Officer at Genocea Biosciences (Nasdaq: GNCA) and Isconova AB for an interim period. He was also a member of the Scottish Scientific Advisory Committee, reporting to the First Minister of Scotland.
As the Independent Chairman of the Board of BiomX Inc, the total compensation of Russell Greig at BiomX Inc is $17,534. There are 4 executives at BiomX Inc getting paid more, with Jonathan Solomon having the highest compensation of $936,565.
Russell Greig is 68, he's been the Independent Chairman of the Board of BiomX Inc since 2019. There are 1 older and 12 younger executives at BiomX Inc. The oldest executive at BiomX Inc is Alan Moses, 72, who is the Independent Director.
Russell's mailing address filed with the SEC is C/O BIOMX INC., 22 EINSTEIN ST., FLOOR 4, , NESS ZIONA,, L3, 7414003.
Over the last 5 years, insiders at BiomX Inc have traded over $332,366 worth of BiomX Inc stock and bought 1,036,414 units worth $787,614 . The most active insiders traders include James Edeerfield Management..., Chidozie Ugwumba, eErez Chimovits. On average, BiomX Inc executives and independent directors trade stock every 68 days with the average trade being worth of $533,749. The most recent stock trade was executed by James Edeerfield Management... on 15 July 2024, trading 11,766,000 units of PHGE stock currently worth $11,648,340.
biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.
BiomX Inc executives and other stock owners filed with the SEC include: